Ocular Therapeutix, Inc. (OCUL)

From the record

Ocular Therapeutix, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Ocular Therapeutix, Inc.'s 9 filed years say what it did: revenue went from $2 million in fiscal 2017 to $52 million in fiscal 2025, up 51% a year; it rose in 7 of 8 years; the deepest fall was 18% from fiscal 2024 to fiscal 2025; net income was positive in 0 of 9 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Ocular Therapeutix, Inc. lost about 41 cents for every dollar of shareholders' money, and gross profitability: its products earned about 6 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 19 cents per dollar of assets, and net share issuance: its share count grew 18.3% over the year (the filed statements).

From the record

Ocular Therapeutix, Inc.'s standing among 315 graded names in its industry family: revenue of $52 million in fiscal 2025 ranks in the top 44% by size; a net margin of -511.9% ranks in the bottom 37%; revenue growth of 0.3% a year over the last 3 filed years ranks in the bottom 39% (its annual reports).

From the record

Ocular Therapeutix, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Dugel, Pravin (Executive Chairman, President and CEO, as filed), filing under that title since 2024-05-28, 2.5 years (bottom 27% of its family); the 18 officers and directors filing in the last fifteen months have been on the record a median of 2.7 years (bottom 13%); 11 officer or director changes were reported on Form 8-K since 2023-11-13, against the 18 people in charge now (bottom 32%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Ocular Therapeutix, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $737 million against no long-term debt tagged leaves 91.2% of its assets as net cash, top 9% of its family; cash from operations less capital spending is -417.5% of revenue (bottom 37%); a gross margin of 87.3% (top 23%); research spending of 379.4% of revenue (top 32%) (its annual report).

From the record

Ocular Therapeutix, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 0.3% a year over the last three filed years against 51% over all 9, slowing (bottom 13% of its family); the newest year grew -18.5% (bottom 27%); research spending grew 54.5% a year (top 7%); capital spending grew 47.9% a year (top 17%) (its annual reports). Ocular Therapeutix, Inc. reported 2 product lines in fiscal 2025: Product at $52 million (100%), Collaboration Revenue at $128 thousand (0%); 0 of 2 grew against the year before (its annual report).

From the record

Ocular Therapeutix, Inc.'s newest year against its own record: revenue of $52 million in fiscal 2025 came in 26.7% below the $71 million its prior three years' pace pointed to (bottom 28% of its family); net income of $266 million against a prior three-year average of $115 million (bottom 12%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 17%) (its annual reports).